



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	Anti-HIV-1 gp41 Monoclonal (50-69)
<b>Catalog Number:</b>	531
<b>Lot Number:</b>	150334
<b>Release Category:</b>	E
<b>Provided:</b>	100 µg of purified antibody at 3.40 mg/mL in PBS
<b>Description:</b>	A monoclonal antibody to HIV-1 gp41
<b>Host:</b>	Human
<b>Titer:</b>	The user should determine the optimal concentration for any application.
<b>Special Characteristics:</b>	<p>This antibody was produced in cell culture and purified by Protein A/G chromatography. It originates from a hybridoma created by fusing EBV-immortalized B-cells from HIV-seropositive individuals and heteromyeloma SHM-D33 cells. Please see the <a href="#">LANL HIV Molecular Database</a> for more information.</p> <p>It reacts with a gp41 peptide spanning aa 579-613 in ELISA. The exact epitope has not been identified. This monoclonal reacts with a conformational determinant which is maintained by an intrachain disulfide bond.</p> <p>This antibody does not inhibit HIV-1-associated cell fusion or mediate neutralization, but it does mediate ADCC. It has been shown to enhance HIV-1 infection.</p> <p>Applications: ELISA, Western Blot, ADCC</p>
<b>Recommended Storage:</b>	Keep the reagent at 4°C for short term storage and at -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.
<b>Contributor:</b>	Dr. Susan Zolla-Pazner

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Isotype:** IgG<sub>1</sub> κ

**References:** Gorny, M. K., Gianakakos, V., Sharpe, S., & Zolla-Pazner, S. (1989). Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A, 86(5), 1624-1628. [PUBMED](#)

Pinter, A., Honnen, W. J., Tilley, S. A., Bona, C., Zaghoulani, H., Gorny, M. K., & Zolla-Pazner, S. (1989). Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol, 63(6), 2674-2679. [PUBMED](#)

Till, M. A., Ghetie, V., May, R. D., Auerbach, P. C., Zolla-Pazner, S., Gorny, M. K., . . . Vitetta, E. S. (1990). Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function. J Acquir Immune Defic Syndr, 3(6), 609-614. [PUBMED](#)

Tyler, D. S., Stanley, S. D., Zolla-Pazner, S., Gorny, M. K., Shadduck, P. P., Langlois, A. J., . . . Weinhold, K. J. (1990). Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol, 145(10), 3276-3282. [PUBMED](#)

Xu, J. Y., Gorny, M. K., Palker, T., Karwowska, S., & Zolla-Pazner, S. (1991). Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol, 65(9), 4832-4838. [PUBMED](#)

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp41 Monoclonal (50-69) from Dr. Susan Zolla-Pazner (cat# 531)." Also include the references cited above in any publications.

Limited to 1 mg per laboratory per year. Patent pending. Corporate requests should be directed in writing to Dr. Susan Zolla-Pazner at the Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1090, New York, NY 10029.

**Also note that contributor will like to be informed at least two weeks before submitting a document for publication or making a public oral presentation of research results obtained from the use of this material in writing or by providing a copy of the publication document.**

**Recipient must not use or incorporate the reagent for commercial purposes.**

**Last Updated** October 25, 2019

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.